DNAmito has the potential to transform cancer treatment and early prediction of chronic disease thus vastly improving patient care.
~ Dr. Martin Brown, Professor of Radiation and Cancer biology at Stanford University
DNAmito enables precise cancer treatment through its proprietary DNA technology and cloud platform. Our products leverage existing and open standards in the industry. DNAmito is vendor agnostic.
For more information on our products, please watch this video
DNAmito brings a strong clinical, experienced product and commercialization team that will augment the science and development team in Europe to be a major player in personalized and precision healthcare. The goal is to improve patient care by bringing our unique and proprietary genomics technology-based products and provide cost effective solutions to the clinicians and the patients.